Most NAD⁺ strategies try to add supply. 5-Amino-1MQ does something different — it stops NAD⁺ raw material from being thrown away. It plugs into the exact node where precursors and TMG already act, from a third direction. Here’s where it fits, and an honest look at the dosing confusion around it.
On the NAD⁺ loop, there’s a node where excess nicotinamide is cleared by an enzyme called NNMT — methylated and excreted, spending a methyl group in the process. That node is a valve: nicotinamide arriving there can either be recycled back into NAD⁺ or wasted down the excretion route. 5-Amino-1MQ is a small molecule that closes the wastage side of that valve. It doesn’t add NAD⁺ raw material; it stops the raw material you already have from being thrown away. Understanding that single move explains both what it does and why it’s discussed alongside NAD⁺, TMG, and fat loss all at once — and it sets up the honest conversation about its very unsettled dosing.
NNMT (nicotinamide N-methyltransferase) takes nicotinamide — which is a salvageable NAD⁺ precursor your cell can recycle back into NAD⁺ — and methylates it into 1-methylnicotinamide, which gets excreted. Every molecule it processes is a bit of NAD⁺ raw material lost, and a methyl group (from SAM, your universal methyl donor) spent to do it. When NNMT is overactive, it siphons off nicotinamide that could have been salvaged. 5-Amino-1MQ competitively inhibits NNMT — so more nicotinamide stays in the salvage pathway (feeding NAMPT, the rate-limiting NAD⁺-building enzyme), and less SAM is spent. The result reported in cell studies is a meaningful rise in NAD⁺ over a couple of days, with increased activity of the NAD⁺-dependent sirtuins.
That widely-cited NAD⁺ rise (about a third, within two days) was measured in a dish of cells — where the "dose" is a concentration in the culture medium (micromolar), not milligrams a person swallows. It shows the mechanism is real, which is genuinely useful. But a cell-culture concentration does not convert into a human capsule size: it says nothing about how much you absorb, how it distributes, or how much reaches your tissues. So "the study that proved it raises NAD⁺" and "the dose you should take" are two completely different questions — and only the first has been answered. Any time you see an impressive lab result next to a milligram number, check whether the result actually came from that dose in a person. Here, it didn't.
This is why it belongs in the NAD⁺-loop conversation: NNMT is a hub three different tools act on, each from a different angle. Precursors (NMN, NR, niacin) add nicotinamide supply. TMG pays the methylation cost — replenishing the methyl pool that clearing excess precursor drains. And 5-Amino-1MQ reduces the wastage at source — blocking the enzyme so less nicotinamide is lost and less SAM is spent in the first place. Add supply, pay the cost, cut the loss: three complementary levers on one node.
NNMT isn’t only about NAD⁺. It’s highly active in fat tissue and liver, where its methyl-spending changes metabolism and epigenetic programming, and elevated NNMT activity in fat has been linked to obesity in several studies. By blocking NNMT, 5-Amino-1MQ is proposed to shift the metabolic balance toward energy expenditure rather than storage — preclinical rodent work reports reduced fat mass driven by increased energy expenditure (not appetite suppression), while preserving lean mass. There’s also a muscle-aging angle: NNMT rises in aging and sarcopenic muscle, so its inhibition is being studied for muscle metabolic function. Much of this runs through the same NAD⁺/SAM restoration — which is why the fat, muscle, and longevity claims all trace back to the one enzyme.
Mechanism. It genuinely inhibits NNMT (characterized in vitro), and NNMT genuinely sits at the NAD⁺/SAM junction. The logic is sound.
Metabolic effects. Fat-loss, energy-expenditure, and NAD⁺-raising results come from animal and cell studies — promising, but not human.
Human use. No completed human trials; long-term safety unknown; sold as an unregulated research chemical (“not for human use”).
The dosing confusion is real, and it has clear causes. Start with the honest baseline: there are no published human pharmacokinetic data and no human trials defining a safe or effective dose. Everything circulating is either animal data or community convention. Here’s what genuinely exists, and why the numbers scatter so wildly:
The animal doses: preclinical mouse studies have used roughly 40–80 mg/kg body weight, given orally or by injection. The extrapolation trap: people take that mouse mg/kg and multiply straight onto a human’s body weight — which is the wrong method and produces enormous numbers (this is the “you need insane doses” talk). Proper cross-species scaling (by body-surface-area) divides that down substantially, landing far lower — but still only an estimate, never tested in people. The community figures: vendor and forum convention clusters around a modest daily oral dose with periodic cycling — but those are convention and marketing, not trial-established, and they sit well below even the surface-area-scaled animal estimate. So the range you hear spans from “modest” to “absurd” precisely because it’s three different guesses derived three different ways, none anchored to human evidence.
Here’s a genuinely clarifying point that sets 5-Amino-1MQ apart from the peptides it’s sold beside. Most research peptides must be injected because they’d be destroyed in digestion. 5-Amino-1MQ is not a peptide — it’s a small, membrane-permeable molecule that is orally bioavailable (a pharmacokinetic study reported meaningful oral bioavailability with a half-life supporting once- or twice-daily dosing). That means the whole rationale for injecting peptides doesn’t apply here: the oral capsule is a legitimate, standard route, and the case for subcutaneous injection is much weaker than for a true peptide. Some inject it anyway chasing higher bioavailability, but there’s no human data showing that’s necessary or better — and injecting an unregulated powder adds sterility and dosing-precision risks of its own. For a small orally-available molecule, “why inject it at all?” is a fair question.
To be precise about the subcutaneous form specifically: no published human study examines it, and no study characterizes how this charged molecule is even absorbed under the skin. The animal work used oral gavage and intraperitoneal injection (a rodent lab route, not human subcutaneous); the single pharmacokinetic study was rat oral bioavailability (~38%). The case for injecting is purely theoretical — bypassing first-pass liver metabolism could raise how much reaches the blood — which is plausible but untested for this compound in people.
And treat the confident vendor numbers with suspicion. Pages selling injectable product cite exact figures like "80% subcutaneous vs 40% oral" — but those aren't from any human study, they contradict each other from site to site (one says 12–18% oral, the next 40–50%), and community "doses" scatter from micrograms to tens of milligrams, a hundred-fold spread. That incoherence is the tell: these are marketing figures filling the gap where real data should be. The one thing the honest sources agree on is that no human trial has validated any dose, by any route.
Because there is no validated human dose, no long-term human safety data, and it’s an unregulated research chemical, the specific dose, route, and cycling are not things to settle from forums or a vendor’s convention — they’re a conversation for a physician, ideally one who can monitor relevant markers. Understanding the mechanism is one thing; deciding to take an investigational NNMT inhibitor, and at what dose, is a medical decision that current evidence simply cannot make for you.
5-Amino-1MQ is an NNMT inhibitor that raises NAD⁺ by closing the wastage valve — stopping nicotinamide from being methylated and excreted, so more is recycled and less SAM is spent. It’s a third lever on the same node where precursors (add supply) and TMG (pay the methyl cost) act, plus a fat/metabolic angle via the same enzyme. Evidence is real in mechanism, promising in animals, unproven in humans. On dosing: there’s no validated human dose — the wild range comes from animal-to-human extrapolation done well vs naively vs community convention — and because it’s orally bioavailable, you don’t need to inject it (capsule is the standard route). Dose and route are a physician call, not a forum one.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment, and it does not recommend any product, dose, route, or protocol. 5-Amino-1MQ is an investigational research chemical sold “for research use only, not for human consumption”; it has no completed human clinical trials, no established human dosing, and unknown long-term safety. Dose figures mentioned are from animal studies or community/vendor convention and are described to explain the surrounding confusion, not as guidance. Any decision to use an investigational compound belongs with a qualified physician using appropriate monitoring. Mechanisms described range from established to speculative.
This lesson relates to these health systems — health works as a connected system, not isolated topics.
Prerequisite: The Mitochondrial Loop: NAD+, Methylation & Glutathione